Compare
Siga Technologies Inc vs Fortress Biotech, Inc. vs Lifevantage Corp vs Sinovac Biotech Ltd
| Latest fiscal year | Siga Technologies Inc SIGA | Fortress Biotech, Inc. FBIO | Lifevantage Corp LFVN | Sinovac Biotech Ltd SVA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $94.57M | $63.26M | $182.59M | $386.01M |
| Revenue growth (YoY) | -31.8% | +9.7% | -20.1% | +6.8% |
| Gross margin | 68.6% (computed) | 66.9% (computed) | 77.6% | 67.9% |
| Operating margin | 25.1% | -111.0% | 3.3% | -127.0% |
| Net margin | 24.6% | 10.8% | 2.8% | -51.5% |
| Net income | $23.28M | $6.82M | $5.07M | -$198.84M |
| EPS (Diluted) | $0.32 | -$0.07 | $0.40 | -$0.83 |
| Operating cash flow | $43.47M | -$65.78M | $10.24M | -$512.18M |
| Free cash flow | n/a | n/a | $6.67M | -$561.10M |
| Cash & equivalents | $154.97M | $79.38M | n/a | $488.25M |
| Total assets | $219.47M | $185.55M | $62.11M | $8.54B |
| Total liabilities | $20.65M | $123.36M | $28.52M | $2.15B |
| Shareholders' equity | $198.82M | $49.87M | $33.59M | $6.40B |
| Return on year-end equity | 11.7% | 13.7% | 15.1% | -3.1% |
| Shares outstanding | 71.61M | 31.36M | 12.52M | 71.86M |
Revenue, most recent five fiscal years
| Fiscal year | Siga Technologies Inc | Fortress Biotech, Inc. | Lifevantage Corp | Sinovac Biotech Ltd |
|---|---|---|---|---|
| Latest | $94.57M Ended 2025-12-31 | $63.26M Ended 2025-12-31 | $182.59M Ended 2026-06-30 | $386.01M Ended 2025-12-31 |
| 1 year earlier | $138.72M Ended 2024-12-31 | $57.67M Ended 2024-12-31 | $228.53M Ended 2025-06-30 | $361.37M Ended 2024-12-31 |
| 2 years earlier | $139.92M Ended 2023-12-31 | $84.51M Ended 2023-12-31 | $200.16M Ended 2024-06-30 | $470.17M Ended 2023-12-31 |
| 3 years earlier | $110.78M Ended 2022-12-31 | $75.74M Ended 2022-12-31 | $213.40M Ended 2023-06-30 | $1.47B Ended 2022-12-31 |
| 4 years earlier | $133.67M Ended 2021-12-31 | $68.79M Ended 2021-12-31 | $206.36M Ended 2022-06-30 | $19.37B Ended 2021-12-31 |